RxDoctor Payments Data

Emily Williams, NP

Nurse Practitioner · Austin, TXNPI 1558049395

Payments from drug & device makers

$705in general payments, 2019–2025

Across 34 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$149
  • Novo Nordisk$110
  • Dexcom, Inc.$44
  • Novartis$33
  • Sanofi-aventis U.S. LLC$33
  • AstraZeneca$29
  • plus $308 from 14 others

What the payments were for

  • Food & beverage$705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$705 in reported general payments places this provider in the 70th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$31,590
Medicare patients
125
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide103$121,513
OzempicSemaglutide78$82,958
JardianceEmpagliflozin35$43,574
TrulicityDulaglutide29$36,207
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$14,688
Gvoke Hypopen 2-PackGlucagon20$12,270
Tresiba Flextouch U-100Insulin Degludec21$11,526
VascepaIcosapent Ethyl12$6,006
Humalog Kwikpen U-100Insulin Lispro23$5,726
Novolog FlexpenInsulin Aspart20$4,594
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,329
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$961
Metformin Hcl ErMetformin Hcl47$648
Rosuvastatin Calcium25$396
Ezetimibe12$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$149$157,720132 claims
Novo NordiskOzempic$110$82,95878 claims
Boehringer IngelheimJardiance$28$43,57435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →